Original Article
Neuropsychopharmacology (2006) 31, 1888–1899. doi:10.1038/sj.npp.1301002; published online 11 January 2006
Preclinical Research
Chronic Olanzapine Treatment Causes Differential Expression of Genes in Frontal Cortex of Rats as Revealed by DNA Microarray Technique
S Hossein Fatemi1, Teri J Reutiman1, Timothy D Folsom1, Christopher Bell1, Lisa Nos1, Peter Fried1, David A Pearce2, Sushmita Singh3, David P Siderovski4, Francis S Willard4 and Mitsunori Fukuda5
- 1Department of Psychiatry, Division of Neuroscience Research, University of Minnesota Medical School, Minneapolis, MN, USA
- 2Department of Biochemistry and Biophysics, Center for Functional Genomics, University of Rochester School of Medicine, Rochester, NY, USA
- 3Biomedical Genomics Center, University of Minnesota, Minneapolis, MN, USA
- 4Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
- 5Fukuda Initiative Research Unit, RIKEN, Wako, Saitama, Japan
Correspondence: Dr SH Fatemi, Department of Psychiatry, Division of Neuroscience Research, University of Minnesota Medical School, MMC 392, 420 Delaware Street SE, Minneapolis, MN 55455, USA. Tel: +1 612 626 3633; Fax: +1 612 624 8935; E-mail: fatem002@umn.edu
Received 16 May 2005; Revised 17 October 2005; Accepted 24 October 2005; Published online 11 January 2006.
Abstract
Recent emerging biochemical data indicate that several important neuroregulatory genes and proteins may be involved in the etiology of schizophrenia and bipolar disorder. Additionally, the same genes appear to be targets of several psychotropic medications that are used to treat these disorders. Recent DNA microarray studies show that genes involved in synaptic neurotransmission, signal transduction, and glutamate/GABA regulation may be differentially regulated in brains of subjects with schizophrenia. We hypothesized that chronic administration of olanzapine to rats would alter expression of various genes that may be involved in the etiology of schizophrenia and mood disorders. Rats were administered olanzapine (N=20, 2 mg/kg/day) or sterile saline intraperitoneally (N=20) daily for 21 days. Control and olanzapine-treated frontal cortices were analyzed using cDNA microarray technology. The results showed significant downregulation of 31 genes and upregulation of 38 genes by greater than two-fold in the drug-treated brains vs controls. Our results provide evidence for altered regulation of genes involved with signal transduction and cell communication, metabolism and energy pathways, transport, immune response, nucleic acid metabolism, and neuronal growth factors. Real-time quantitative RT-PCR analysis verified the direction and magnitude of change in six genes of interest: calbindin 3, homer 1, regulator of G-protein signaling (RGS) 2, pyruvate kinase, Reelin and insulin 2. Western blotting showed significant upregulation in protein products for Reelin 410 and Reelin 180 kDa and downregulation for NMDA3B and RGS2. Our results show for the first time that olanzapine causes changes in levels of several important genes that may be involved in the etiology and treatment of schizophrenia and other psychiatric disorders.
Keywords:
olanzapine, DNA microarray, schizophrenia, bipolar disorder, Reelin, insulin
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
REVIEWS
Oestrogen as a neuroprotective hormone
Nature Reviews Neuroscience Review (01 Jun 2002)
Protein palmitoylation: a regulator of neuronal development and function
Nature Reviews Neuroscience Review (01 Oct 2002)
RESEARCH
Olanzapine increases glucogenesis by multiple pathways in brain and muscle
Molecular Psychiatry Letter
Prepulse Inhibition Deficits in GAD65 Knockout Mice and the Effect of Antipsychotic Treatment
Neuropsychopharmacology Original Article
Neuropsychopharmacology Original Article

